Should I Stop Taking Terbinafine If I Get a Rash?

Stop taking terbinafine and contact your prescriber if you develop a rash while on the medication. That guidance comes directly from dermatology literature and is consistent across case reports and reviews: patients should be counseled to discontinue terbinafine at the onset of any skin eruption and seek medical advice about what to do next.¹ The reason is straightforward but worth understanding in detail, because terbinafine rashes range from mild and self-limiting to genuinely life-threatening, and you cannot tell early on which category yours falls into.

How Common Are Skin Reactions on Terbinafine

Skin side effects are reported in roughly 2% of people taking oral terbinafine for fungal nail or skin infections.² Among those reactions, nonspecific rashes account for about 6% of all reported adverse events, itching for about 3%, and hives for about 1%.³ Those numbers make skin complaints the single largest category of terbinafine side effects reported to drug-safety agencies. In New Zealand’s adverse-event database, for instance, over half of all terbinafine reports described some form of skin reaction, ranging from itching and photosensitivity to severe blistering conditions.⁴

Most of these reactions are mild. A faint, slightly itchy rash that appears a week or two into treatment is the most typical presentation, and it usually resolves once the drug is stopped. But “usually mild” is exactly the problem: the early stages of severe and potentially fatal skin reactions can look almost identical to a harmless drug rash. A pinkish, flat rash on the trunk could be a simple maculopapular eruption that will fade in days, or it could be the opening act of something much worse. Because there is no reliable way to distinguish the two at home, the standing medical advice is to treat any new rash as a reason to stop the drug and get evaluated.

Mild Rashes Versus Dangerous Reactions

The benign end of the spectrum includes maculopapular rashes (flat or slightly raised red patches), fixed drug eruptions that appear in the same spot each time, hives, and rashes that look like pityriasis rosea, a common viral-type skin condition. These tend to be uncomfortable but not dangerous, and they generally clear up within days to a couple of weeks once you stop the medication.

The severe end is a different story. Terbinafine has been linked to several serious cutaneous drug reactions:

• Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): These involve widespread skin blistering and peeling that can affect mucous membranes, eyes, and internal organs. SJS/TEN requires hospitalization, often in a burn unit, and carries a significant mortality rate.
• Acute generalized exanthematous pustulosis (AGEP): A rapid eruption of tiny sterile pustules over red, swollen skin, usually with fever. AGEP from terbinafine carries roughly a 5% mortality rate.⁵
• Erythroderma: Redness and scaling covering most of the body surface, which can destabilize temperature regulation and fluid balance.
• Erythema multiforme: Target-shaped lesions, sometimes with mucosal involvement, that can progress to more serious conditions if not caught early.

In a study of ten patients who developed severe skin reactions to terbinafine, five had erythema multiforme, one had erythroderma, one had severe hives, one developed a pityriasis rosea-like eruption, and two experienced worsening of pre-existing psoriasis. All ten required that the drug be stopped.¹ A separate study looking at antifungal-related skin reactions found terbinafine to be the most common culprit drug, linked to both mild eruptions and severe reactions including SJS/TEN and AGEP.⁶

Skin Reactions That Can Come With Internal Problems

One of the less obvious reasons to take a terbinafine rash seriously is that skin eruptions sometimes accompany damage elsewhere in the body. AGEP, for example, has been reported alongside drug-induced liver inflammation in the same patient, meaning the skin reaction was a visible signal of a broader immune response that was also affecting the liver.⁵ Terbinafine-related liver injury is well known on its own, but the combination of a skin eruption and rising liver enzymes suggests a systemic hypersensitivity reaction rather than a purely skin-level event.

Terbinafine has also been associated with dermatomyositis, an inflammatory condition that affects skin and muscles. One proposed explanation involves terbinafine triggering the death of endothelial cells (the cells lining blood vessels), which displaces cellular components and creates new targets for the immune system. The resulting antibody response can attack blood vessels in the skin and muscles simultaneously.⁷ A separate mechanism involves the drug pushing the immune system toward a type of response dominated by inflammatory signaling molecules. Lab studies have shown that terbinafine increases the release of pro-inflammatory signals from immune cells, which may help explain why some patients develop widespread immune-mediated reactions rather than just localized skin irritation.⁸

A rash by itself might be benign. A rash alongside fever, fatigue, dark urine, muscle pain, or joint aches raises the stakes considerably. When your doctor evaluates a terbinafine-related skin eruption, they will likely check your liver function (and possibly muscle enzymes) as well, because what looks like a straightforward skin problem can reflect something going on systemically. It is worth noting that elevated liver enzymes in someone on terbinafine could also point to rhabdomyolysis (muscle breakdown) rather than direct liver toxicity, since damaged muscle tissue releases enzymes that overlap with the ones measured in standard liver tests.⁹

Terbinafine Can Trigger Psoriasis and Lupus

Two autoimmune-related skin conditions deserve special mention because they look different from typical drug rashes and have distinct implications for treatment.

Terbinafine can trigger new-onset psoriasis in people who have never had it before, or flare existing psoriasis, sometimes converting stable plaque-type disease into a more aggressive pustular form. In one series, two patients with known plaque psoriasis experienced flares within about two weeks of starting terbinafine, while another developed pustular psoriasis from scratch after 27 days on the drug. In all cases, the psoriasis improved or resolved after the medication was stopped and appropriate psoriasis treatment was started.¹⁰ Across published literature, roughly two dozen cases of terbinafine-triggered psoriasis flares or new psoriasis have been described, which is enough to represent a real pattern even if the absolute risk remains low. Because of this association, some dermatologists are cautious about prescribing oral terbinafine to patients with a history of psoriasis, since other antifungal options exist that do not carry this particular risk.

The lupus connection is also well documented. Terbinafine has been linked to subacute cutaneous lupus erythematosus (SCLE), which causes annular or scaly patches on sun-exposed skin. In a series of five patients who developed SCLE while taking terbinafine, several had a prior history of lupus or related features like photosensitivity and positive autoimmune blood markers. The researchers suggested that people with an existing history of lupus, unexplained photosensitivity, or positive antinuclear antibodies may be at higher risk for this reaction.¹¹ Terbinafine has been specifically categorized as carrying a relatively high risk for drug-induced SCLE compared to other medications known to trigger the condition.¹²

The practical upshot: if you develop scaly, ring-shaped, or photosensitive skin lesions while on terbinafine, make sure your doctor considers drug-induced lupus as a possibility rather than treating it as a simple rash. And if you already carry a lupus or psoriasis diagnosis, discuss the risks before starting terbinafine.

Why the Rash Might Not Disappear Immediately After Stopping

Terbinafine has an unusually long effective presence in the body. The drug concentrates in skin, nails, and fat tissue and is released slowly, which is actually the property that makes it effective against nail fungus (treatments work because the drug stays in the nail plate for weeks after you stop swallowing pills). The flip side is that if you develop an adverse reaction, the drug does not wash out of your system quickly. Skin reactions can persist or even worsen for several days after the last dose, especially severe eruptions that have already established a strong immune response.

This is one reason why earlier discontinuation leads to better outcomes. The further into a severe reaction you get before stopping, the more drug has accumulated in tissue and the more momentum the immune response has built. A rash caught at day two and met with immediate discontinuation will, in most cases, resolve faster and with less intervention than one that is given another week to develop. Some patients in published case reports required corticosteroids, immunosuppressants, or inpatient care because the reaction had progressed too far before the medication was stopped.

Genetic Factors That Affect Your Risk

Not everyone who takes terbinafine faces the same likelihood of a reaction. Research into terbinafine-related liver injury has uncovered a strong genetic link that likely extends to at least some skin reactions, given the overlap between skin and liver hypersensitivity events. In a study of 11 patients of European ancestry who developed cholestatic liver injury from terbinafine, 10 (about 91%) carried a specific immune gene variant called HLA-A*33:01. That gene variant has a carrier frequency of only about 1.6% in European-ancestry populations, which means it is rare in the general population but dramatically overrepresented among people who react badly to the drug. Among East Asian patients in the same study, a closely related variant (HLA-A*33:03) was found instead.¹³

HLA genes encode proteins on cell surfaces that help the immune system distinguish self from non-self. When a drug binds to an HLA protein in an unusual way, the immune system can misidentify the drug-HLA complex as foreign and mount an aggressive response. Molecular docking studies showed that terbinafine can interact with the HLA-A*33:01 and HLA-A*33:03 proteins, which fits the pattern seen in other drug hypersensitivity syndromes. This kind of genetic testing is not routinely performed before prescribing terbinafine at present, but the finding helps explain why severe reactions cluster in certain patients while the vast majority tolerate the drug without problems.

Figuring Out Whether Terbinafine Was Really the Cause

If you develop a rash while taking terbinafine alongside other medications, pinning the reaction on the right drug matters. Standard allergy tests like skin prick tests and patch tests have limited sensitivity for terbinafine reactions. In one published case, both the skin prick test and patch test came back negative in a patient who had experienced a clear delayed allergic reaction to the drug. A different approach, the lymphocyte transformation test, gave a positive result, correctly confirming terbinafine as the cause. This test works by exposing a patient’s immune cells to the suspected drug in a lab dish and measuring whether they mount a response.¹⁴

The lymphocyte transformation test is not widely available and is mostly used in specialized allergy or dermatology centers. For most people, the diagnosis is made clinically: you started terbinafine, a rash appeared, and it improved after the drug was stopped. That pattern is usually sufficient for a working diagnosis, especially when the timing fits (most terbinafine skin reactions appear within the first few weeks of treatment, though some emerge later). A drug re-challenge, where you restart the medication to see if the rash returns, is generally not recommended because the second reaction can be more severe than the first.

What to Do Instead of Terbinafine

If you need to stop terbinafine because of a rash, your fungal infection still needs treatment. The main systemic alternative for nail fungus caused by dermatophytes is itraconazole, which can be given in a pulsed dosing schedule (one week on, three weeks off, repeated for several cycles). Current evidence supports continuous terbinafine as the preferred first-line treatment for dermatophyte nail infections, but itraconazole remains an established option specifically for patients who cannot tolerate terbinafine, have contraindications to it, or have failed prior terbinafine therapy.¹⁵ Itraconazole has its own side-effect profile (including potential liver and cardiac effects), but it works through a completely different mechanism, so cross-reactivity with terbinafine skin reactions is not expected.

For milder fungal infections, topical antifungals (applied directly to the skin or nail) sidestep most of the systemic side-effect concerns entirely, since very little of the drug reaches the bloodstream. Topical terbinafine cream, for what it is worth, carries a far lower risk of the kinds of serious skin reactions described above, because the systemic exposure is negligible. The trade-off is that topical treatments are much less effective for nail infections, where the drug needs to reach the nail bed from within. For skin-only fungal infections like athlete’s foot or ringworm, a topical antifungal is often sufficient and avoids systemic risk altogether.

People With Psoriasis or Lupus Need a Different Conversation

If you carry a diagnosis of psoriasis, lupus, or another autoimmune skin condition, the decision to use oral terbinafine deserves careful discussion before you ever fill the prescription. The risk of triggering a disease flare is real enough that some dermatologists consider terbinafine a suboptimal first choice for nail fungus in psoriasis patients, given that alternatives exist. As one group of authors put it, terbinafine may not be the best first-line therapy for onychomycosis in patients with psoriasis. Similarly, people with a history of SCLE, positive antinuclear antibodies, or unexplained photosensitivity may be better served by a different antifungal from the start.¹¹

This does not mean terbinafine is categorically off-limits. In patients without autoimmune risk factors, it remains the most effective oral antifungal for dermatophyte nail infections. The researchers who first flagged the lupus connection stated explicitly that they did not consider terbinafine an unsafe drug in general. The point is that certain patient backgrounds shift the risk-benefit calculation, and those patients should know about the shift before they start treatment rather than after a rash appears.